Adcock Ingram manufactures, distributes and markets a wide range of medicines and healthcare products. Three local manufacturing sites offer significant capacity in steriles, liquids and tablet/capsule manufacturing. Adcock Ingram is thus well positioned to supply the state sector in line with the Department of Trade and Industry’s local manufacturing objectives.

Adcock Ingram has recently undertaken a capital expansion project costing R1.5 billion which was primarily focused on the regulatory compliance status of the three manufacturing facilities situated in Gauteng. The investment in the High Volume Liquids facility at Clayville has created significant capacity in liquids while expansion at the Wadeville facility has increased capacity for tablet and capsule manufacture and in particular, antiretrovirals (ARV). Adcock Ingram was awarded 25% by volume, of the South African Government ARV tender for 2013/2014.

The Company’s focus is to produce high quality pharmaceuticals in the most environmentally friendly and cost effective way by achieving operational excellence.

Adcock Ingram is taking part in the Department of Trade and Industry (DTI) Workplace Challenge initiative that has been introduced in our three local facilities. This two and a half year programme is aimed at achieving continuous improvement. The Company expects to start reaping benefits during the next two years and thereafter.

Below is a detailed summary of each of our manufacturing facilities, click on each icons to see full description on our sites: